Flavopiridol HCl | HMR-1275 Hydrochloride | CDK Inhibitor

首页 / / / / Flavopiridol HCl

Flavopiridol HCl {[allProObj[0].p_purity_real_show]}

货号：A180731 同义名： HMR-1275 Hydrochloride; L86-8275 Hydrochloride

Flavopiridol HCl competes with ATP to inhibit CDKs including CDK1, CDK2, CDK4 and CDK6 with IC50 of ~ 40 nM.

Flavopiridol HCl 化学结构
CAS号：131740-09-5

Flavopiridol HCl 3D分子结构
CAS号：131740-09-5

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]}	现货	1周咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

Flavopiridol HCl 纯度/质量文件产品仅供科研

货号：A180731 标准纯度： {[allProObj[0].p_purity_real_show]} 产品说明书

批次查询：批次纯度: COA SDS NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: 更多 >

CDK 亚型比较

产品名称	Cdc ↓ ↑	CDK1 ↓ ↑	CDK19 ↓ ↑	CDK2 ↓ ↑	CDK3 ↓ ↑	CDK4 ↓ ↑	CDK5 ↓ ↑	CDK6 ↓ ↑	CDK7 ↓ ↑	CDK8 ↓ ↑	CDK9 ↓ ↑	CLK ↓ ↑	其他靶点	纯度
XL413 HCl	++++ Cdc7, IC50: 3.4 nM													99%+
SU9516		+++ CDK1, IC50: 40 nM		+++ CDK2, IC50: 22 nM		++ CDK4, IC50: 200 nM								99%+
RO-3306		+++ CDK1, Ki: 20 nM											ERK,SGK	98%
R547		++++ CDK1/CyclinB, Ki: 2 nM		++++ CDK2/CyclinE, Ki: 3 nM		++++ CDK4/CyclinD1, Ki: 1 nM								99%+
BMS-265246		++++ CDK1/CyclinB, IC50: 6 nM		++++ CDK2/CyclinE, IC50: 9 nM		+ CDK4/CyclinD, IC50: 230 nM								99%+
NU6027		+ CDK1, Ki: 2.5 μM		+ CDK2, Ki: 1.3 μM									DNA-PK	98%
Purvalanol A	++++ Cdc2/CyclinB, IC50: 4 nM			+++ CDK2/CyclinE, IC50: 35 nM CDK2/CyclinA, IC50: 70 nM		+ CDK4/CyclinD1, IC50: 850 nM								99%+
SCH900776				++ CDK2, IC50: 0.16 μM										99%+
AUZ 454				++++ CDK2(A144C), Kd: 9.7 nM CDK2(C118L), Kd: 18.6 nM										99%+
A-674563 HCl				++ CDK2, Ki: 46 nM									PKA	99%
JNJ-7706621		++++ CDK1/CyclinB, IC50: 9 nM		++++ CDK2/CyclinE, IC50: 3 nM CDK2/CyclinA, IC50: 4 nM	++ CDK3/CyclinE, IC50: 58 nM	+ CDK4/CyclinD1, IC50: 253 nM		++ CDK6/CyclinD1, IC50: 175 nM						99%+
AT7519		++ CDK1/CyclinB, IC50: 210 nM		++ CDK2/CyclinA, IC50: 47 nM	+ CDK3/CyclinE, IC50: 360 nM	++ CDK4/CyclinD1, IC50: 100 nM	+++ CDK5/p35, IC50: 13 nM	++ CDK6/CyclinD3, IC50: 170 nM			++++ CDK9/CyclinT, IC50: <10 nM			98+%
PHA-793887		++ CDK1/CyclinB, IC50: 60 nM		++++ CDK2/CyclinE, IC50: 8 nM CDK2/CyclinA, IC50: 8 nM		++ CDK4/CyclinD1, IC50: 62 nM	++++ CDK5/p25, IC50: 5 nM		++++ CDK7/CyclinH, IC50: 10 nM		++ CDK9/CyclinT1, IC50: 138 nM			99%+
Milciclib		+ CDK1/CyclinB, IC50: 398 nM		++ CDK2/CyclinE, IC50: 363 nM CDK2/CyclinA, IC50: 45 nM		++ CDK4/CyclinD1, IC50: 160 nM	+ CDK5/p35, IC50: 265 nM		++ CDK7/CyclinH, IC50: 150 nM					99%+
Kenpaullone		+ CDK1/CyclinB, IC50: 0.4μM		+ CDK2/CyclinE, IC50: 7.5μM CDK2/CyclinA, IC50: 0.68μM			+ CDK5/p35, IC50: 0.85μM							98%
SNS-032				+++ CDK2/CyclinE, IC50: 48 nM CDK2/CyclinA, IC50: 38 nM			+ CDK5/p35, IC50: 340 nM		++ CDK7/CyclinH, IC50: 62 nM		++++ CDK9/CyclinT, IC50: 4 nM			99%+
Dinaciclib		++++ CDK1, IC50: 3 nM		++++ CDK2, IC50: 1 nM			++++ CDK5, IC50: 1 nM				++++ CDK9, IC50: 4 nM			99%+
PHA-767491 HCl	++++ Cdc7, IC50: 10 nM	+ CDK1, IC50: 250 nM		+ CDK2, IC50: 240 nM			+ CDK5, IC50: 460 nM				+++ CDK9, IC50: 34 nM		MK2	99%
(R)-Roscovitine	+ Cdc2/CyclinB, IC50: 0.65 μM			+ CDK2/CyclinE, IC50: 0.7 μM CDK2/CyclinA, IC50: 0.7 μM			++ CDK5/p35, IC50: 0.16 μM							99%+
Narazaciclib						++++ CDK4/CyclinD1, IC50: 3.87 nM		++++ CDK6/CyclinD1, IC50: 9.82 nM					RET	99%+
Palbociclib						++++ CDK4/CyclinD1, IC50: 11 nM CDK4/CyclinD3, IC50: 9 nM		+++ CDK6/CyclinD2, IC50: 15 nM						99%
Abemaciclib						++++ CDK4, IC50: 2 nM		++++ CDK6, IC50: 10 nM						99%
Ribociclib						++++ CDK4, IC50: 10 nM		+++ CDK6, IC50: 39 nM						98%
Palbociclib isethionate						++++ CDK4/CyclinD1, IC50: 11 nM CDK4/CyclinD3, IC50: 9 nM		+++ CDK6/CyclinD2, IC50: 15 nM						99%+
BS-181 HCl									+++ CDK7, IC50: 21 nM					99%+
(E/Z)-THZ1 2HCl									++++ CDK7, IC50: 3.2 nM					99%+
LDC4297									++++ CDK7, IC50: 0.13 nM					99%+
Senexin A			+ CDK19, Kd: 0.31 μM							+ CDK8, Kd: 0.83 μM				99%
MSC2530818										++++ CDK8, IC50: 2.6 nM				99%+
Wogonin											✔			99%+
Riviciclib HCl		++ CDK1/CyclinB, IC50: 79 nM		+ CDK2/CyclinE, IC50: 2.54 μM CDK2/CyclinA, IC50: 224 nM		++ CDK4/CyclinD1, IC50: 63 nM		+ CDK6/CyclinD3, IC50: 396 nM	+ CDK7/CyclinH, IC50: 2.87 μM		+++ CDK9/CyclinT1, IC50: 20 nM			98%
LDC000067				+ CDK2, IC50: 2.441 μM							++ CDK9, IC50: 44 nM			98%
Flavopiridol		+++ CDK1, IC50: 40 nM		+++ CDK2, IC50: 40 nM		+++ CDK4, IC50: 40 nM		+++ CDK6, IC50: 40 nM	+ CDK7, IC50: 300 nM		+++ CDK9, IC50: 20 nM			99%+
LY2857785									+ CDK7, IC50: 0.246 μM	+++ CDK8, IC50: 0.016 μM	+++ CDK9, IC50: 0.011 μM			99%+
AZD-5438		+++ CDK1, IC50: 16 nM		++++ CDK2, IC50: 6 nM							+++ CDK9, IC50: 20 nM			99%+
ML167												++ CLK4, IC50: 136 nM Dyrk1B , IC50: 1648 nM		99%+
(E/Z)-TG003												+++ mCLK4, IC50: 15 nM mCLK1, IC50: 200 nM		99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Flavopiridol HCl 生物活性

描述

At a concentration of 2 μM, Flavopiridol significantly triggers ER stress in CLL cells, leading to cell death via the activation of IRE1, ASK1, and potentially downstream caspases^[1]. Flavopiridol causes a strong increase in the expression of various PRGs over 4-24 hours of treatment. It has both immediate and prolonged effects on PRG expression levels. Even in serum-deprived cells that are later re-exposed to serum, Flavopiridol suppresses gene expression initially, but later, genes such as JUNB, GADD45B, and EGR1 experience an upsurge in their expression due to Flavopiridol^[2].

Flavopiridol HCl 细胞研究

细胞系	浓度	检测类型	检测时间	活性说明	数据源
A2780 cell		Function assay		Inhibition of A2780 cell clonogenic assay， IC50=15 μM	11063609
A2780/DDP-R human ovarian carcinoma cell		Proliferation assay		Inhibition of A2780/DDP-R human ovarian carcinoma cell proliferation, IC50=38 nM	12190313
A2780/DDP-S human ovarian carcinoma cell		Proliferation assay		Inhibition of A2780/DDP-S human ovarian carcinoma cell proliferation, IC50=56 nM	12190313
A2780/TAX-R human ovarian carcinoma cell		Proliferation assay		Inhibition of A2780/TAX-R human ovarian carcinoma cell proliferation, IC50=78 nM	12190313

Flavopiridol HCl 动物研究

Dose	Mice: 5 mg/kg, 7.5 mg/kg^[3] (i.p.) Rat: 0.01 mg/kg- 5 mg/kg^[4] (i.p.)
Administration	i.p.

Flavopiridol HCl 临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT02520011	Acute Myeloid Leukemia	Phase 2	Recruiting	December 2019	-
NCT00006485	Unspecified Adult Solid Tumor,... 展开 >> Protocol Specific 收起 <<	Phase 1	Completed	-	United States, New York ... 展开 >> Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10021 收起 <<
NCT00087282	Liver Cancer	Phase 2	Completed	-	United States, New York ... 展开 >> Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10021 收起 <<

Flavopiridol HCl 参考文献

[1]Senderowicz AM. The cell cycle as a target for cancer therapy: basic and clinical findings with the small molecule inhibitors flavopiridol and UCN-01. Oncologist. 2002;7 Suppl 3:12-9.

[2]Carlson BA, Dubay MM, et al. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res. 1996 Jul 1;56(13):2973-8.

Flavopiridol HCl 实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

2.28mL

0.46mL

0.23mL

11.41mL

2.28mL

1.14mL

22.82mL

4.56mL

2.28mL

Flavopiridol HCl 技术信息

CAS号	131740-09-5
分子式	C₂₁H₂₁Cl₂NO₅
分子量	438.3
SMILES Code	O=C1C=C(C2=CC=CC=C2Cl)OC3=C1C(O)=CC(O)=C3[C@@H]4[C@H](O)CN(C)CC4.[H]Cl
MDL No.	MFCD26792554

别名	HMR-1275 Hydrochloride; L86-8275 Hydrochloride; L-868,275; HL 275; Flavopiridol (hydrochloride); DSP-2033; HMR-1275; Alvocidib; NSC 649890; Alvocidib Hydrochloride; Flavopiridol Hydrochloride
运输	蓝冰
InChI Key	LGMSNQNWOCSPIK-LWHGMNCYSA-N
Pubchem ID	9910986

存储条件

In solvent -20°C:3-6个月-80°C:12个月

Pure form Inert atmosphere, 2-8°C

动物实验配方

PO 0.5% CMC-Na 50 mg/mL suspension

大规格询价

* 公司或机构名称：

* 姓名：

* 电话：

* 邮箱： * 国家/区域： * 需求量：

* 货号：

* CAS号：

* 产品名称：在线留言：

请填写此表格索取QC报告。我们很快就会发送到您的邮箱。您的信息在我们这里是安全的。*是必填项.

产品名称： * 货号：

* 姓名：

* 电话：

* 邮箱： * 公司或机构名称： * 部门：留言给我们：

摩尔计算器

计算溶液所需的质量，体积或浓度。 Ambeed 摩尔浓度计算器基于以下方程式：

浓度 (mol/L) × 体积 (L) × 分子量 (g/mol)=质量 (g)

浓度

体积

分子量

质量

*在制备母液时，请始终参考产品标签或 MSDS / COA（在产品页面可下载）上所显示的对应批次产品的分子量。

靶点

靶点	数值

总药量计算器

动物实验：给药剂量 mg/kg 动物体重 g 动物数量只每天给药次给药天

需要的总药量： mg

工作液计算器

动物实验：给药剂量 mg/kg 动物体重 g 给药体积 μL

您需要配制的工作液浓度为：mg/mL

细胞研究

细胞系	浓度	检测类型	检测时间	活性说明	数据源

A2780 cell	Function assay		Inhibition of A2780 cell clonogenic assay， IC50=15 μM	11063609
A2780/DDP-R human ovarian carcinoma cell	Proliferation assay		Inhibition of A2780/DDP-R human ovarian carcinoma cell proliferation, IC50=38 nM	12190313
A2780/DDP-S human ovarian carcinoma cell	Proliferation assay		Inhibition of A2780/DDP-S human ovarian carcinoma cell proliferation, IC50=56 nM	12190313
A2780/TAX-R human ovarian carcinoma cell	Proliferation assay		Inhibition of A2780/TAX-R human ovarian carcinoma cell proliferation, IC50=78 nM	12190313
A2780/TAX-S human ovarian carcinoma cell	Proliferation assay		Inhibition of A2780/TAX-S human ovarian carcinoma cell proliferation, IC50=65 nM	12190313
A431 human squamous cell	Proliferation assay		Inhibition of A431 human squamous cell carcinoma cell proliferation, IC50=75 nM	12190313
A549 human lung carcinoma cell	Proliferation assay		Inhibition of A549 human lung carcinoma cell proliferation, IC50=96 nM	12190313
ABAE human fibroblast cell	Proliferation assay		Inhibition of ABAE human fibroblast cell proliferation, IC50=45 nM	12190313
CACO-2 human colon carcinoma cell	Proliferation assay		Inhibition of CACO-2 human colon carcinoma cell proliferation, IC50=86 nM	12190313
CCRF-CEM human leukemia cell	Proliferation assay		Inhibition of CCRF-CEM human leukemia cell proliferation, IC50=52 nM	12190313
HCT116 cell	Function assay		Inhibition of HCT116 cell clonogenic assay, IC50=13 μM	11063609
HCT116 human colon carcinoma cell	Proliferation assay		Inhibition of HCT116 human colon carcinoma cell proliferation, IC50=18 nM	12190313
HCT116/VM46 human colon carcinoma cell	Proliferation assay		Inhibition of HCT116/VM46 human colon carcinoma cell proliferation, IC50=21 nM	12190313
HCT116/VP35 human colon carcinoma cell	Proliferation assay		Inhibition of HCT116/VP35 human colon carcinoma cell proliferation, IC50=17 nM	12190313
HL60 human leukemia cell	Proliferation assay		Inhibition of HL60 human leukemia cell proliferation, IC50=46 nM	12190313
Hs 27 human fibroblast cell	Proliferation assay		Inhibition of Hs 27 human fibroblast cell proliferation, IC50=51 nM	12190313
human A2780 cell line	Proliferation assay	72 h	Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay, IC50=71 nM	15027863
human A2780 cells	Cytotoxic assay	24 h	Cytotoxicity against human A2780 cells after 24 hrs by MTT assay, GI50=23 nM	23301767
human A2780 cells	Cytotoxic assay	72 h	Cytotoxicity against human A2780 cells after 72 hrs by MTT assay, GI50=29 nM	23301767
human A2780 cells	Cytotoxic assay	48 h	Cytotoxicity against human A2780 cells after 48 hrs by MTT assay, GI50=31 nM	23301767
human A2780 cells	Function assay		Inhibition of cdk-mediated NPM phosphorylation at thr199 in human A2780 cells	18469809
human A2780 cells	Function assay	24 h	Inhibition of cdk-mediated Rb phosphorylation at thr821 in human A2780 cells after 24 hrs	18469809
human HMEC1 cells	Cytotoxic assay	24 h	Cytotoxicity against human HMEC1 cells after 24 hrs by MTT assay, GI50=61 nM	23301767
human HMEC1 cells	Cytotoxic assay	48 h	Cytotoxicity against human HMEC1 cells after 48 hrs by MTT assay, GI50=62 nM	23301767
human HMEC1 cells	Cytotoxic assay	72 h	Cytotoxicity against human HMEC1 cells after 72 hrs by MTT assay, GI50=66 nM	23301767
human MRC5 cells	Cytotoxic assay	72 h	Cytotoxicity against human MRC5 cells after 72 hrs by MTT assay, GI50=28 nM	23301767
human MRC5 cells	Cytotoxic assay	48 h	Cytotoxicity against human MRC5 cells after 48 hrs by MTT assay, GI50=39 nM	23301767
human MRC5 cells	Cytotoxic assay	24 h	Cytotoxicity against human MRC5 cells after 24 hrs by MTT assay, GI50=49 nM	23301767
human NCI60 cells	Proliferation assay	72 h	Antiproliferative activity against human NCI60 cells after 72 hrs by sulforhodamine B assay, GI50=74.7 nM	21080703
human NCI60 cells	Proliferation assay	72 h	Antiproliferative activity against human NCI60 cells assessed as lethal effect after 72 hrs by sulforhodamine B assay, LC50=0.904 μM	21080703
human ovarian (A2780) cancer cell	Cytotoxic assay		Cytotoxic effect on human ovarian (A2780) cancer cell line, IC50=71 nM	15125971
ID8 cells	Proliferation assay		Antiproliferative activity against ID8 cells, IC50=7 nM	17123821
K562 human leukemia cell	Proliferation assay		Inhibition of K562 human leukemia cell proliferation, IC50=0.13 μM	12190313
LNCaP human prostate carcinoma cell	Proliferation assay		Inhibition of LNCaP human prostate carcinoma cell proliferation	12190313
LS174T human colon carcinoma cell	Proliferation assay		Inhibition of LS174T human colon carcinoma cell proliferation, IC50=65 nM	12190313
LX-1 human lung carcinoma	Proliferation assay		Inhibition of LX-1 human lung carcinoma proliferation, IC50=75 nM	12190313
M109 mouse lung carcinoma cell	Proliferation assay		Inhibition of M109 mouse lung carcinoma cell proliferation, IC50=80 nM	12190313
MCF7 cells	Proliferation assay		Antiproliferative activity against MCF7 cells, IC50=26 nM	17123821
MCF-7 human breast carcinoma cell	Proliferation assay		Inhibition of MCF-7 human breast carcinoma cell proliferation, IC50=66 nM	12190313
MCF-7 tumor cell	Proliferation assay		Inhibition of MCF-7 tumor cell proliferation	10843211
Mia PaCa-2 cell	Function assay		Inhibition of Mia PaCa-2 cell clonogenic assay, IC50=36 μM	11063609
MIP human colon carcinoma cell	Function assay		Inhibition of MIP human colon carcinoma cell line, IC50=0.12 μM	12190313
MLF mouse lung fibroblast cell	Proliferation assay		Inhibition of MLF mouse lung fibroblast cell proliferation, IC50=72 nM	12190313
OVCAR-3 human ovarian carcinoma cell	Proliferation assay		Inhibition of OVCAR-3 human ovarian carcinoma cell proliferation, IC50=54 nM	12190313
PC3 cell	Function assay		Inhibition of PC3 cell clonogenic assay, IC50=10 μM	11063609
PC3 human prostate carcinoma cell	Proliferation assay		Inhibition of PC3 human prostate carcinoma cell proliferation, IC50=66 nM	12190313
Sf9 cells	Function assay		Inhibition of recombinant cyclin A/CDK2 expressed in Sf9 cells, IC50=12 nM	17904366
SKBR-3 human breast carcinoma cell	Proliferation assay		Inhibition of SKBR-3 human breast carcinoma cell proliferation, IC50=77 nM	12190313

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT02520011	Acute Myeloid Leukemia	Phase 2	Recruiting	December 2019	-
NCT00006485	Unspecified Adult Solid Tumor,... 展开 >> Protocol Specific 收起 <<	Phase 1	Completed	-	United States, New York ... 展开 >> Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10021 收起 <<
NCT00087282	Liver Cancer	Phase 2	Completed	-	United States, New York ... 展开 >> Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10021 收起 <<
NCT00007917	Unspecified Adult Solid Tumor,... 展开 >> Protocol Specific 收起 <<	Phase 1	Completed	-	United States, Massachusetts ... 展开 >> Massachusetts General Hospital Cancer Center Boston, Massachusetts, United States, 02114 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 收起 <<
NCT00634244	-		Completed	-	-
NCT00021073	Unspecified Adult Solid Tumor,... 展开 >> Protocol Specific 收起 <<	Phase 1	Completed	-	United States, Minnesota ... 展开 >> Mayo Clinic Rochester, Minnesota, United States, 55905 收起 <<
NCT00470197	Adult Acute Megakaryoblastic L... 展开 >>eukemia (M7) Adult Acute Minimally Differentiated Myeloid Leukemia (M0) Adult Acute Monoblastic Leukemia (M5a) Adult Acute Monocytic Leukemia (M5b) Adult Acute Myeloblastic Leukemia With Maturation (M2) Adult Acute Myeloblastic Leukemia Without Maturation (M1) Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) Adult Acute Myelomonocytic Leukemia (M4) Adult Erythroleukemia (M6a) Adult Pure Erythroid Leukemia (M6b) Malignant Neoplasm Recurrent Adult Acute Lymphoblastic Leukemia Recurrent Adult Acute Myeloid Leukemia 收起 <<	Phase 1	Completed	-	United States, Maryland ... 展开 >> Johns Hopkins University Baltimore, Maryland, United States, 21287-8936 United States, Wisconsin University of Wisconsin Hospital and Clinics Madison, Wisconsin, United States, 53792 收起 <<
NCT00042874	Unspecified Adult Solid Tumor,... 展开 >> Protocol Specific 收起 <<	Phase 1	Completed	-	United States, New York ... 展开 >> Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 收起 <<
NCT00634244	Adult Acute Megakaryoblastic L... 展开 >>eukemia (M7) Adult Acute Minimally Differentiated Myeloid Leukemia (M0) Adult Acute Monoblastic Leukemia (M5a) Adult Acute Monocytic Leukemia (M5b) Adult Acute Myeloblastic Leukemia With Maturation (M2) Adult Acute Myeloblastic Leukemia Without Maturation (M1) Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) Adult Acute Myelomonocytic Leukemia (M4) Adult Erythroleukemia (M6a) Adult Pure Erythroid Leukemia (M6b) Recurrent Adult Acute Myeloid Leukemia 收起 <<	Phase 2	Completed	-	United States, Alabama ... 展开 >> University of Alabama at Birmingham Birmingham, Alabama, United States, 35294 United States, Arizona Mayo Clinic in Arizona Scottsdale, Arizona, United States, 85259 United States, Florida Mayo Clinic in Florida Jacksonville, Florida, United States, 32224-9980 United States, Illinois Northwestern University Chicago, Illinois, United States, 60611 United States, Iowa Siouxland Hematology Oncology Associates Sioux City, Iowa, United States, 51101 United States, Maryland Johns Hopkins University/Sidney Kimmel Comprehensive Cancer Center Baltimore, Maryland, United States, 21287 United States, Massachusetts Tufts Medical Center Boston, Massachusetts, United States, 02111 United States, Minnesota Mayo Clinic Rochester, Minnesota, United States, 55905 United States, Ohio The Jewish Hospital Cincinnati, Ohio, United States, 45236 United States, Pennsylvania Geisinger Medical Center Danville, Pennsylvania, United States, 17822-2001 Geisinger Medical Center-Cancer Center Hazleton Hazleton, Pennsylvania, United States, 18201 Penn State Milton S Hershey Medical Center Hershey, Pennsylvania, United States, 17033-0850 Lewistown Hospital Lewistown, Pennsylvania, United States, 17044 Geisinger Medical Group State College, Pennsylvania, United States, 16801 Mount Nittany Medical Center State College, Pennsylvania, United States, 16803 Geisinger Wyoming Valley Wilkes-Barre, Pennsylvania, United States, 18711 United States, Tennessee Vanderbilt-Ingram Cancer Center Nashville, Tennessee, United States, 37232 United States, Wisconsin University of Wisconsin Hospital and Clinics Madison, Wisconsin, United States, 53792 Froedtert and the Medical College of Wisconsin Milwaukee, Wisconsin, United States, 53226 Israel Rambam Medical Center Haifa, Israel, 31096 收起 <<
NCT00407966	-		Completed	-	-
NCT00407966	Adult Acute Basophilic Leukemi... 展开 >>a Adult Acute Eosinophilic Leukemia Adult Acute Megakaryoblastic Leukemia (M7) Adult Acute Minimally Differentiated Myeloid Leukemia (M0) Adult Acute Monoblastic Leukemia (M5a) Adult Acute Monocytic Leukemia (M5b) Adult Acute Myeloblastic Leukemia With Maturation (M2) Adult Acute Myeloblastic Leukemia Without Maturation (M1) Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) Adult Acute Myelomonocytic Leukemia (M4) Adult Erythroleukemia (M6a) Adult Pure Erythroid Leukemia (M6b) Secondary Acute Myeloid Leukemia Untreated Adult Acute Myeloid Leukemia 收起 <<	Phase 2	Completed	-	United States, Maryland ... 展开 >> Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore, Maryland, United States, 21287 收起 <<
NCT00795002	-		Completed	-	-
NCT00795002	Acute Myeloid Leukemia With Mu... 展开 >>ltilineage Dysplasia Following Myelodysplastic Syndrome Adult Acute Megakaryoblastic Leukemia (M7) Adult Acute Minimally Differentiated Myeloid Leukemia (M0) Adult Acute Monoblastic Leukemia (M5a) Adult Acute Monocytic Leukemia (M5b) Adult Acute Myeloblastic Leukemia With Maturation (M2) Adult Acute Myeloblastic Leukemia Without Maturation (M1) Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities Adult Acute Myeloid Leukemia With Del(5q) Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) Adult Acute Myelomonocytic Leukemia (M4) Adult Erythroleukemia (M6a) Adult Pure Erythroid Leukemia (M6b) Secondary Acute Myeloid Leukemia Untreated Adult Acute Myeloid Leukemia 收起 <<	Phase 2	Completed	-	United States, Maryland ... 展开 >> Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore, Maryland, United States, 21287 United States, Washington Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium Seattle, Washington, United States, 98109 收起 <<
NCT00046917	Unspecified Adult Solid Tumor,... 展开 >> Protocol Specific 收起 <<	Phase 1	Completed	-	United States, New York ... 展开 >> Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10065 收起 <<
NCT01349972	Acute Myeloid Leukemia With Mu... 展开 >>ltilineage Dysplasia Following Myelodysplastic Syndrome Adult Acute Minimally Differentiated Myeloid Leukemia (M0) Adult Acute Monoblastic Leukemia (M5a) Adult Acute Monocytic Leukemia (M5b) Adult Acute Myeloblastic Leukemia With Maturation (M2) Adult Acute Myeloblastic Leukemia Without Maturation (M1) Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities Adult Acute Myeloid Leukemia With Del(5q) Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) Adult Acute Myelomonocytic Leukemia (M4) Adult Erythroleukemia (M6a) Adult Pure Erythroid Leukemia (M6b) Secondary Acute Myeloid Leukemia Untreated Adult Acute Myeloid Leukemia 收起 <<	Phase 2	Completed	-	United States, Arizona ... 展开 >> Mayo Clinic Scottsdale-Phoenix Scottsdale, Arizona, United States, 85259 United States, Florida Moffitt Cancer Center Tampa, Florida, United States, 33612 United States, Georgia Blood and Marrow Transplant Group of Georgia Atlanta, Georgia, United States, 30342 United States, Illinois University of Chicago Chicago, Illinois, United States, 60637 United States, Maryland University of Maryland/Greenebaum Cancer Center Baltimore, Maryland, United States, 21201 Johns Hopkins University/Sidney Kimmel Comprehensive Cancer Center Baltimore, Maryland, United States, 21287 United States, Minnesota Mayo Clinic Rochester, Minnesota, United States, 55905 United States, North Carolina University of North Carolina Chapel Hill, North Carolina, United States, 27599 United States, Tennessee Vanderbilt-Ingram Cancer Center Nashville, Tennessee, United States, 37232 United States, Texas Baylor University Medical Center Dallas, Texas, United States, 75246 United States, Virginia Virginia Commonwealth University Richmond, Virginia, United States, 23298 收起 <<
NCT00079352	Unspecified Adult Solid Tumor,... 展开 >> Protocol Specific 收起 <<	Phase 1	Completed	-	United States, New Mexico ... 展开 >> University of New Mexico Albuquerque, New Mexico, United States, 87106 收起 <<
NCT01349972	-		Completed	-	-
NCT00991952	-		Completed	-	-
NCT00072436	Unspecified Adult Solid Tumor,... 展开 >> Protocol Specific 收起 <<	Phase 1	Completed	-	United States, Massachusetts ... 展开 >> Massachusetts General Hospital Cancer Center Boston, Massachusetts, United States, 02114 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 United States, New York Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 收起 <<
NCT01076556	Chronic Lymphocytic Leukemia ... 展开 >> Prolymphocytic Leukemia Recurrent Small Lymphocytic Lymphoma Refractory Chronic Lymphocytic Leukemia Stage I Chronic Lymphocytic Leukemia Stage I Small Lymphocytic Lymphoma Stage II Chronic Lymphocytic Leukemia Stage II Small Lymphocytic Lymphoma Stage III Chronic Lymphocytic Leukemia Stage III Small Lymphocytic Lymphoma Stage IV Chronic Lymphocytic Leukemia Stage IV Small Lymphocytic Lymphoma 收起 <<	Phase 1	Terminated	-	United States, Ohio ... 展开 >> Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States, 43210 收起 <<
NCT00991952	Adenocarcinoma of the Gastroes... 展开 >>ophageal Junction Diffuse Adenocarcinoma of the Stomach Intestinal Adenocarcinoma of the Stomach Mixed Adenocarcinoma of the Stomach Recurrent Gastric Cancer Stage IIIA Gastric Cancer Stage IIIB Gastric Cancer Stage IIIC Gastric Cancer Stage IV Gastric Cancer 收起 <<	Phase 2	Completed	-	United States, California ... 展开 >> City of Hope Duarte, California, United States, 91010 UC Davis Comprehensive Cancer Center Sacramento, California, United States, 95817 United States, Illinois University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States, 60637-1470 United States, Michigan University of Michigan Ann Arbor, Michigan, United States, 48109 United States, New York Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10065 收起 <<
NCT00735930	Anemia Chroni... 展开 >>c Lymphocytic Leukemia Prolymphocytic Leukemia Recurrent Small Lymphocytic Lymphoma Refractory Chronic Lymphocytic Leukemia Thrombocytopenia 收起 <<	Phase 1	Completed	-	United States, Ohio ... 展开 >> Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States, 43210 收起 <<
NCT00957905	Recurrent Extragonadal Seminom... 展开 >>a Recurrent Malignant Extragonadal Germ Cell Tumor Recurrent Malignant Extragonadal Non-Seminomatous Germ Cell Tumor Recurrent Malignant Testicular Germ Cell Tumor Recurrent Ovarian Germ Cell Tumor Stage III Testicular Cancer Stage IV Extragonadal Non-Seminomatous Germ Cell Tumor Stage IV Extragonadal Seminoma Stage IV Ovarian Germ Cell Tumor 收起 <<	Phase 2	Completed	-	United States, California ... 展开 >> Tower Cancer Research Foundation Beverly Hills, California, United States, 90211-1850 City of Hope Comprehensive Cancer Center Duarte, California, United States, 91010 USC / Norris Comprehensive Cancer Center Los Angeles, California, United States, 90033 University of California Davis Comprehensive Cancer Center Sacramento, California, United States, 95817 United States, Illinois University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States, 60637 United States, Minnesota Mayo Clinic Rochester, Minnesota, United States, 55905 United States, New York Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10065 United States, Pennsylvania UPMC-Presbyterian Hospital Pittsburgh, Pennsylvania, United States, 15213 University of Pittsburgh Cancer Institute (UPCI) Pittsburgh, Pennsylvania, United States, 15232 United States, Wisconsin Riverview Hospital Wisconsin Rapids, Wisconsin, United States, 54494 收起 <<
NCT00082784	Extranodal Marginal Zone Lymph... 展开 >>oma of Mucosa-Associated Lymphoid Tissue Nodal Marginal Zone Lymphoma Recurrent Adult Diffuse Large Cell Lymphoma Recurrent Adult Diffuse Mixed Cell Lymphoma Recurrent Adult Diffuse Small Cleaved Cell Lymphoma Recurrent Grade 1 Follicular Lymphoma Recurrent Grade 2 Follicular Lymphoma Recurrent Grade 3 Follicular Lymphoma Recurrent Mantle Cell Lymphoma Recurrent Marginal Zone Lymphoma Refractory Plasma Cell Myeloma Splenic Marginal Zone Lymphoma Waldenstrom Macroglobulinemia 收起 <<	Phase 1	Completed	-	United States, Florida ... 展开 >> Moffitt Cancer Center Tampa, Florida, United States, 33612 United States, Pennsylvania University of Pittsburgh Cancer Institute Pittsburgh, Pennsylvania, United States, 15232 University of Pittsburgh Pittsburgh, Pennsylvania, United States, 15232 United States, South Carolina Medical University of South Carolina Charleston, South Carolina, United States, 29425 United States, Virginia Virginia Commonwealth University/Massey Cancer Center Richmond, Virginia, United States, 23298 收起 <<
NCT00098579	Gastrointestinal Stromal Tumor... 展开 >> Recurrent Adult Soft Tissue Sarcoma Stage IV Adult Soft Tissue Sarcoma 收起 <<	Phase 1	Completed	-	United States, New York ... 展开 >> Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 收起 <<
NCT00047307	Adenocarcinoma of the Pancreas... 展开 >> Recurrent Pancreatic Cancer Stage II Pancreatic Cancer Stage III Pancreatic Cancer Stage IV Pancreatic Cancer 收起 <<	Phase 1	Completed	-	United States, New York ... 展开 >> Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10065 收起 <<
NCT00957905	-		Completed	-	-

Flavopiridol HCl {[allProObj[0].p_purity_real_show]}

Flavopiridol HCl 纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Flavopiridol HCl 质控信息

Flavopiridol HCl 生物活性

Flavopiridol HCl 细胞研究

Flavopiridol HCl 动物研究

Flavopiridol HCl 临床研究

Flavopiridol HCl 参考文献

Flavopiridol HCl 实验方案

Flavopiridol HCl 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Flavopiridol HCl {[allProObj[0].p_purity_real_show]}

Flavopiridol HCl 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Flavopiridol HCl 质控信息

Flavopiridol HCl 生物活性

Flavopiridol HCl 细胞研究

Flavopiridol HCl 动物研究

Flavopiridol HCl 临床研究

Flavopiridol HCl 参考文献

Flavopiridol HCl 实验方案

Flavopiridol HCl 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Flavopiridol HCl 纯度/质量文件产品仅供科研